In anti-PD-1 clinical trials for NSCLC, melanoma, and renal cell carcinoma, the incidence rates of thyroid dysfunction range from 2.500 to 14%, with a mean rate of 5.900% for hypothyroidism and 3.300% for hyperthyroidism [24–29]. Here, PDCD1 is linked to hypothyroidism.